abstract |
Use of a human IL-1beta binding antibody for the manufacture of a medicament for the treatment of juvenile rheumatoid arthritis in a patient, comprising: at least one antigen binding site comprising a first domain that has a deamino acid sequence such as that shown in SEQ ID NO: 1, and a second domain that has an amino acid sequence as shown in SEQ ID NO: 2. |